Zhitong Finance App News, Cornerstone Pharmaceutical-B (02616) issued an announcement. The latest research data on CS5001 (ROR1 ADC), a major product in the company's R&D pipeline 2.0, will be displayed in the form of a poster at the 2024 American Society of Clinical Oncology (ASCO) annual meeting. This year's ASCO Annual Meeting will be held in Chicago, USA from May 31 to June 4, 2024.

Details are as follows: Title: First global multi-center human study of CS5001, a novel ROR1 antibody-conjugated drug, in the treatment of advanced solid tumors and lymphoma patients with advanced solid tumors and lymphoma. Poster presentation time: June 1, 2024, 9:00-12:00 a.m. (US Central Daylight Time). Abstract publication number: 3023.

According to reports, CS5001 is an antibody-conjugated drug (ADC) that targets the receptor tyrosine kinase-like orphan receptor 1 (ROR1) in the clinical phase. CS5001 has a unique design using tumor-specific activated pyrrolobenzodiazepine (PBD) pretoxin payload (payload) and linker (linker). CS5001 only reaches the tumor and is swallowed by tumor cells before its ligand is cut in lysosomes by a specific enzyme that is highly expressed in tumor cells, which in turn releases the pre-PBD toxin, which is then activated within the tumor cell, thereby killing the tumor cell. This “dual control” mechanism of linker plus pre-toxin effectively reduces toxicity issues associated with traditional PBD payloads and obtains a larger safety window. CS5001 has been shown to have complete tumor inhibitory effects in several preclinical cancer models, and has shown good serum half-life and pharmacokinetic characteristics. These will all be translated into broad therapeutic indicators for various physical and hematologic malignancies. Furthermore, CS5001 uses targeted coupling technology to obtain accurate drug antibody ratios (DAR), which is easy to achieve homogenous production and large-scale production.

In October 2020, Cornerstone Pharmaceuticals and LEGOChem Biosciences, Inc. (LCB) reached a licensing agreement for the development and commercialization of CS5001. CS5001 was initially co-synthesized by leading Korean biotech companies LCB and ABL Bio. Under the terms of the agreement, Cornerstone Pharmaceuticals obtained exclusive development and commercialization rights for CS5001 in other regions of the world other than Korea.

Cornerstone Pharmaceuticals (HKSE: 2616) is a biopharmaceutical company focusing on research, development and commercialization of innovative cancer immunotherapy and precision therapy drugs to meet the urgent medical needs of cancer patients in China and around the world. Established at the end of 2015, Cornerstone Pharmaceuticals has assembled a management team with rich experience in new drug development, clinical research and commercial operation. With tumor immunotherapy combination therapy as the core, the company has established a rich product pipeline composed of 12 tumor drug candidates. Since its establishment, Cornerstone Pharmaceuticals has received approval for 14 new drug marketing applications for various drugs (including avonib). A number of late-stage drug candidates are in critical clinical trials or registration stages. Cornerstone Pharmaceuticals' vision is to become a world-renowned biopharmaceutical company leading the way to overcoming cancer.